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ex Hormones as
ovel Risk Biomarkers
or Atherosclerosis in
eripheral Vascular Disease*
eter P. Liu, MD, FACC,†‡§
asahiro Fukuoka, MD, PHD†
oronto and Ottawa, Ontario, Canada
therosclerosis respects no vascular territory, and its com-
lications can be acute and devastating, as exemplified by
yocardial infarction, stroke, or sudden death. Peripheral
rterial disease (PAD) is a harbinger of generalized athero-
clerosis, and its relentless progression is associated with
rofound disability, peripheral limb loss, and strong associ-
tion with coronary and carotid diseases. Risk factors or
iomarkers for atherosclerosis are useful for risk stratifica-
ion, primary and secondary prevention, and to establish
argets for treatment. Traditional risk biomarkers for ath-
rosclerosis are well known, including smoking, hyperten-
ion, diabetes, lipid abnormalities, and family history,
mong others.
See page 1070
While general risk biomarkers are well known, there are
ome regional vascular territory differences in the relative
trengths of association of these markers. For example, in
eripheral vascular disease, smoking has a particular potent
ffect on disease severity and progression, while hyperten-
ion has less of an impact on outcome. However, robust risk
arkers for PAD are not commonly available.
ex Hormones as Risk Markers for PAD
n this issue of the Journal, Tivesten et al. (1) demonstrated
n a cross-sectional study the association between endoge-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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oronto, Toronto, Ontario, Canada; ‡Toronto General Research Institute, Univer-
ity Health Network, Toronto, Ontario, Canada; and the §Institute of Circulatory
nd Respiratory Health, Canadian Institutes of Health Research, Ottawa and
oronto, Ontario, Canada. Supported, in part, by grants from the Heart and Strokea
oundation of Ontario and the Canadian Institutes of Health Research. Dr. Liu is the
eart and Stroke/Polo Chair Professor of Medicine at the University of Toronto.ous circulating sex hormone levels and ankle-brachial
ndex (ABI) in 3,014 elderly men who were enrolled in the
wedish arm of the MrOS (Osteoporotic Fractures in Men)
tudy, with an average age 75.4 years. The ABI reflects the
tate of arterial perfusion in the lower limb and, when
easured carefully, is a useful index of peripheral vascular
ealth. Serum-free testosterone was positively associated
ith ABI, suggesting a vascular protective link, whereas free
stradiol was negatively associated with ABI.
This is certainly the largest cohort to date linking sex
ormone levels with PAD in the elderly men who are at
reatest risk for the latter. While the interaction of sex
ormones and atherosclerosis remains complex and at times
ontroversial, this finding is consistent with the overall
ccumulated data to date on testosterone and estrogen’s
elationship with vascular atherosclerosis (Table 1).
Sex hormone imbalance in elderly men is coming into
rominence. Hypogonadism in aging men is increasingly
ecognized as a prevalent condition: 20% of men older than
0 years, 30% of those older than 70 years, and 50% those
lder than 80 years of age. The hypogonadal state in men
as been found to be associated with an increased cardio-
ascular risk (2). In contrast, in a placebo-controlled study
f elderly men with chronic stable angina, daily supplemen-
ation with a low-dose testosterone for several weeks led to
ymptomatic improvement (3). The findings of this current
tudy can be viewed in light of these earlier observations.
The relationship between endogenous estrogen and ac-
eleration of atherosclerosis is also being increasingly rec-
gnized. Testosterone is converted to estradiol by aromatase
n tissues of men, albeit the conversion rate is slow, around
.2%. Ultimately, 80% of plasma estradiol in men originates
rom aromatization of testosterone and androstenedione,
nd no more than 20% is secreted by the testes. However,
he cumulative plasma estradiol levels in some elderly men
re higher than corresponding levels in postmenopausal
omen. Serum estradiol levels in older men have been
ositively correlated to the burden of coronary heart disease
4) and carotid artery disease (5).
ontroversies Regarding
ormones and Atherosclerosis
owever, the relationship between hormones and athero-
clerosis is not without its controversies. The observation
hat coronary disease develops in women on the average of
0 years later in life compared with men and the increase in
ncidence of coronary disease after menopause led to a
ypothesis that estrogen protects against atherosclerotic
omplications in women. However, disappointingly, the
esults from large randomized trials of estrogen replace-
ent therapy in postmenopausal women, such as the
omen’s Health Initiative, failed to confirm any cardio-
ascular benefit of estrogen both for primary and second-
ry prevention (6).
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Editorial Comment September 11, 2007:1077–9To extend these observations on estrogen further, appli-
ation of estrogens to men, for example as a component of
he chemotherapy for prostate cancer, has also been associ-
ted with serious side effects of deep venous thrombosis and
ncreases in cardiovascular-related death.
otential Biological Mechanisms
therosclerosis, from the initial macrophage infiltration
nto the subintima of the blood vessel wall, to the eventual
laque rupture, is a process driven by inflammation. Estro-
en in the appropriate context can act as a proinflammatory
gent.
Exposure of mononuclear inflammatory cells to estradiol
ncreases the production of interferon-, which is a major
nflammatory cytokine that predisposes to atherosclerosis,
nd in turn decreases the production of anti-inflammatory
ytokines (7). Furthermore, cultured human endothelial
ells, when exposed to estradiol, are predisposed to death via
poptosis through the Fas/FasL pathway (8). Exogenous
dministration of estrogen increases plasma and tissue levels
f matrix metalloproteinases, with the latter contributing to the
hinning of the fibrous cap of atherosclerotic plaque, facilitat-
ng rupture. Interestingly, male estrogen receptor- knockout
ice exhibit decreased susceptibility to atherosclerosis (9).
Testosterone appears to have the opposite effect to
strogen in terms of atherogenesis. Testosterone supple-
entation directly protects castrated cholesterol-fed male
abbits from atherosclerosis (10). Androgens, including
estosterone, have been shown to suppress the activity of
roinflammatory cytokines while enhancing the activities of
nti-inflammatory factors. Testosterone also inhibits in-
ammatory cell adhesion to vascular endothelium, the
arliest step in atherosclerosis, through down-regulation of
dhesion molecules on endothelial cells. Testosterone sup-
resses expression of vascular cell adhesion molecule-1 by its
erivative, 5-dihydrotestosterone (11).
estosterone and PAD: Association or Causal?
n a cross-sectional study such as MrOS, the positive
ssociation between ABI and serum-free testosterone levels
ay be directly causal, or associated with each other due to
ther intermediary factors. While the foregoing biological
echanisms may provide a direct causal relationship be-
omparison of the Effects of Androgens and Estrogens on Atherosc
Table 1 Comparison of the Effects of Androgens and Estrogens
Androgens
High
Endogenous Levels
Exogenous
Administration
Coronary artery system 2 men (3,14)
Peripheral arterial system
Carotid artery
Lower extremity 2 men (1)
 decreased risk of atherosclerotic complications;1  increased risk of atherosclerotic compween estradiol with proatherosclerosis and androgens with tntiatherosclerosis effects, sex hormones may also act indi-
ectly through other vascular risk factors.
Specifically, low testosterone levels in men are associated
ith insulin resistance, an atherogenic lipid profile, and the
isk of cardiovascular diseases (2,12). Because androgens are
mportant regulators of the total fat mass and its distribu-
ion, hypogonadism in men is also associated with obesity.
onversely, androgen replacement therapy in elderly men
as beneficial effects on the profile of several cardiovascular
isk factors, including lipid profiles and decreased fat
ass (2,13).
Basic laboratory investigations also support these clinical
bservations. Testosterone deficiency by castration enhances
therosclerosis in male mice, which is exhibited by an
nfavorable profile in low-density lipoprotein metabolism.
nockout of androgen receptor gene in male mice shows
educed insulin sensitivity and impaired glucose tolerance
ssociated with obesity (14).
mplications for Clinical Practice
he study by Tivesten et al. (1) therefore represents the
argest study to date linking ABI positively to serum-free
estosterone and negatively to estrodiol. While this is an
ssociation found in a cross-sectional study, the findings are
onsistent with other studies linking the same hormone
arkers for atherosclerosis. There are also fundamental
iological mechanisms explaining these associations.
However, for the markers to be useful clinically, the
esults will need to be replicated in other cohorts. The
arkers should also be relatively stable in the serum, and
ave significant independent contributions to prognosis
rom other existing known markers, such as low-density
ipoproteins, smoking status, fasting plasma glucose, and
thers.
However, to be a true risk factor rather than just a
iomarker for atherosclerosis or peripheral vascular disease,
ne would need to complete the loop by showing that
herapeutic interventions aimed at, for example, increasing
estosterone levels, truly can alter vascular outcomes. Real-
zing the challenges in the hormone replacement therapy
n postmenopausal women, this will be a significant
ndertaking.
However, realizing that estrogen may be proinflamma-
ic Coronary and Peripheral Artery Disease
therosclerotic Coronary and Peripheral Artery Disease
Estrogens
Low
Endogenous Levels
High
Endogenous Levels
Exogenous
Administration
1 men (4,12) 1 men (2,4) 1 women (6)
1 men (4) 1 men (5) 1 women (6)
1 men (1)
s.lerot
on Aory and accelerates atherosclerosis, whenever estrogen ad-
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September 11, 2007:1077–9 Editorial Commentinistration is contemplated, a thorough search for under-
ying risk factors for vascular disease should be done for the
atient. This would apply to both women in the perimeno-
ause setting and men undergoing treatment for prostate
ancer. If very high vascular risk exists for the patient, the
strogen exposure should be carefully evaluated in terms of
isk versus benefit, accompanied by aggressive management
f the known existing risk factors for vascular disease.
An intriguing question remains as to whether we should
onsider testosterone replacement therapy in elderly men
ith low levels of intrinsic testosterone and multiple risk
actors for atherosclerosis. The purpose is to attenuate the
rogression of atherosclerosis, but this treatment may have
dditional benefit for improving quality of life and other risk
actors as well. These types of questions are triggered by
pidemiologic study such as that by Tivesten et al. (1), but
an only be clarified in time through fundamental investi-
ations, and carefully designed and conducted clinical trials.
eprint requests and correspondence: Dr. Peter P. Liu, Institute
f Circulatory and Respiratory Health, CIHR, NCSB 11-1266,
00 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada.
-mail: peter.liu@utoronto.ca.
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